Surgical Outcomes in Gastric Cancer

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

The enormous influence of the surgeon on outlook in cancer was stressed by Professor Cornelis van de Velde of the Department of Surgery, Leiden University Medical Center, the Netherlands, during the 1997 European Cancer Conference.

The enormous influence of the surgeon on outlook in cancer was stressed by Professor Cornelis van de Velde of the Department of Surgery, Leiden University Medical Center, the Netherlands, during the 1997 European Cancer Conference.

“Quality of surgery can make the most tremendous difference to your chances of survival and the quality of a patient’s remaining life,” said Professor van de Velde. “In rectal cancer, for example, the local recurrence rate can vary enormously between surgeons, from 5% to 50% or 60%, and this can affect not only your risk of dying of metastases, but the degree of suffering. Many local recurrences in rectal cancer are untreatable and cause immense and unbearable symptoms.”

“Survival rates in gastric and rectal cancer can vary as much as 5% to 10% between different surgeons, more than the effect gained from adjuvant treatment.” Professor van de Velde continued. “Morbidity, mortality and survival vary substantially between surgeons. Also more extensive surgery does not necessarily improve survival, so addressing the issues about individual surgical performance is a major issue.” 

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content